EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study

Wirksamkeit und Sicherheit von Dimdazenil bei erwachsenen Patient:innen mit Insomnie: Phase-II-RCT, multizentrisch, doppelblind, placebokontrolliert, Parallelgruppenstudie

Yanpeng Li, Ruoxi Zhang, Yanling Zhou, Cungang Bao, Zhaocun Lin, Chunyan Chen, Jingjing He, Zhiping Jin, Lihua Song, Min Zhang, Sigen Guo, Yu Jiang und 1 weitere

SLEEP · 08.02.2024 · 47 (2)

DOI: 10.1093/sleep/zsad271 ↗

Auf einen Blick

Bei Erwachsenen mit Insomnie verbesserte Dimdazenil mehrere objektive und subjektive Schlafparameter gegenüber Placebo. Für einzelne Dosen waren die Effekte zeitabhängig.

Fragestellung

Wirkt Dimdazenil bei Erwachsenen mit Insomnie wirksam und sicher im Vergleich zu Placebo?

Methode

Randomisierte, doppelblinde, placebokontrollierte Parallelgruppenstudie; 18–65 Jahre; orale Gabe von Placebo oder Dimdazenil 1,5, 2,5 oder 5 mg für 14 Tage.

Ergebnisse

288 Patient:innen erhielten mindestens 1 Dosis. TST besser unter 1,5, 2,5 und 5 mg an Tag 1/2; an Tag 13/14 unter 2,5 und 5 mg. LPS, SE und subjektive Schlafparameter verbesserten sich teils dosisabhängig. Häufigste TEAEs: Schwindel, Vertigo, Schwäche.

Schlussfolgerung der Autor:innen

Dimdazenil 1,5, 2,5 und 5 mg verbesserte bestimmte objektive und subjektive Schlafparameter bei guter Sicherheitsverträglichkeit. Die Autor:innen sehen es als potenziell neue Behandlung der Insomnie.

Kernaussagen

  • TST verbessert unter allen 3 Dosen an Tag 1/2
  • An Tag 13/14 blieben 2,5 und 5 mg wirksam
  • Häufigste TEAEs: Schwindel, Vertigo und Schwäche

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift SLEEP, online erschienen am 21.10.2023. Verfasst von Yanpeng Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Shanghai Changzheng Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objectives To evaluate the efficacy and safety of Dimdazenil, a positive allosteric modulator with selectivity for α1, α5 subunit-containing GABAA receptors, on sleep variables in patients with insomnia disorder.

Methods

In this randomized, double-blind, placebo-controlled trial, adults (18–65 years) with insomnia disorder were randomized (1:1:1:1 to receive daily oral placebo, Dimdazenil (1.5, 2.5, or 5 mg) for 14 days. The primary efficacy outcome was the total sleep time (TST) on day 1/2 and day 13/14, measured by polysomnography. The secondary outcome measures included (1) latency to persistent sleep (LPS), sleep efficiency (SE), wake after sleep onset (WASO) and number of awakenings (NAW) on days 1/2 and day 13/14, and (2) the average subjective sleep latency (sSL), total sleep time (sTST), wake after sleep onset (sWASO) and number of awakenings (sNAW) recorded in sleep diary and sleep questionnaire, and the evaluation of insomnia severity index. Rebound insomnia, withdrawal, and treatment-emergent adverse events were also assessed.

Results

Of 569 patients screened, 288 (76.4% female) were randomized and received one dose. For the primary outcomes, TST was significantly improved in the Dimdazenil 1.5, 2.5, and 5 mg group compared with the placebo group at day 1/2, and significantly improved in the Dimdazenil 2.5 and 5 mg groups compared with the placebo group at day 13/14. The Least Squares Means (standard errors) and 95% Confidence Intervals for the three active doses compared to placebo are 25.5 (8.31), (9.16, 41.89) for the 1.5 mg dose; 17.4 (8.19), (1.29, 33.55) for the 2.5 mg dose; 22.8 (8.15), (6.72, 38.80) for the 5 mg dose on day 1/2. Corresponding data on day 13/14 are 7.6 (8.07), (−8.24, 23.53) and 19.3 (8.06), (3.43, 35.17) and 18.2 (7.95), (2.49, 33.80). LPS was significantly reduced in the Dimdazenil 5 mg group compared with the placebo group on day 1/2. SE was significantly improved in the Dimdazenil 1.5 and 5 mg group compared with the placebo group at day 1/2. In the subjective sleep parameters, sSL on average was significantly lower in the Dimdazenil 1.5, 2.5, and 5 mg groups compared with the placebo group. sTST on average was significantly higher in the Dimdazenil 1.5, 2.5, and 5 mg groups compared with the placebo group. The most common TEAEs were dizziness, vertigo, and weakness with no clinically relevant treatment-related serious adverse events.

Conclusions

Dimdazenil of 1.5, 2.5, and 5 mg improved certain objective and subjective sleep outcomes in people with insomnia disorder, with a favorable safety profile. These findings suggested that Dimdazenil may represent a promising new treatment for insomnia disorder, a prevalent condition with limited effective and safe treatments available. Clinical Trial Information A multicenter, randomized, double-blind, multidose, placebo parallel controlled phase II clinical study of EVT201 in the treatment of insomnia disorders (http://www.chinadrugtrials.org), with the number of CTR20150664.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersAdultFemaleHumansMaleDouble-Blind MethodHypnotics and SedativesPolysomnographySleepTreatment OutcomeAdolescentYoung AdultMiddle AgedAged

Stichwörter der Autor:innen

DimdazenilGABAA receptorsinsomnia disorderpolysomnographypositive allosteric modulator

Substanzen

Hypnotics and Sedatives

Autor:innen und Institutionen

  • Neurology Department, Shanghai Changzheng Hospital, Shanghai, China.
  • Shanghai Research Institute, Zhejiang Jingxin Pharmaceutical Co., Ltd, Shanghai, China.
  • The president's office, Zhejiang Jingxin Pharmaceutical Co., Ltd, Zhejiang, China.

Zitieren

APA

Li, Y., Zhang, R., Zhou, Y., Bao, C., Lin, Z., Chen, C., He, J., Jin, Z., Song, L., Zhang, M., Guo, S., Jiang, Y., & Zhao, Z. (2024). Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study. SLEEP, 47(2). https://doi.org/10.1093/sleep/zsad271

Vancouver

Li Y, Zhang R, Zhou Y, Bao C, Lin Z, Chen C, et al. Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study. SLEEP. 2024;47(2). doi:10.1093/sleep/zsad271

BibTeX
@article{Li2024,
  author = {Li, Yanpeng and Zhang, Ruoxi and Zhou, Yanling and Bao, Cungang and Lin, Zhaocun and Chen, Chunyan and He, Jingjing and Jin, Zhiping and Song, Lihua and Zhang, Min and Guo, Sigen and Jiang, Yu and Zhao, Zhongxin},
  title = {Efficacy and safety of Dimdazenil in the adult insomnia patients: a phase II randomized, multicenter, double-blind, placebo-controlled, and parallel-group study},
  journal = {SLEEP},
  year = {2024},
  volume = {47},
  number = {2},
  doi = {10.1093/sleep/zsad271}
}
Kostenlos starten →